MX374244B - Compuesto de fosforamidato de nucleosido novedoso y su uso. - Google Patents

Compuesto de fosforamidato de nucleosido novedoso y su uso.

Info

Publication number
MX374244B
MX374244B MX2015011473A MX2015011473A MX374244B MX 374244 B MX374244 B MX 374244B MX 2015011473 A MX2015011473 A MX 2015011473A MX 2015011473 A MX2015011473 A MX 2015011473A MX 374244 B MX374244 B MX 374244B
Authority
MX
Mexico
Prior art keywords
compound
novel nucleoside
nucleoside phosphoramidate
phosphoramidate compound
stereoisomer
Prior art date
Application number
MX2015011473A
Other languages
English (en)
Other versions
MX2015011473A (es
Inventor
Cang Zhang
Dezhong Wang
Di Zhang
Hongyan Chen
Liwen Zhao
Sheng Bi
Xian Zhang
Yang Nan
Yiping Gao
Yong Wang
Yuxiu Li
Original Assignee
Nanjing Sanhome Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Sanhome Pharmaceutical Co Ltd filed Critical Nanjing Sanhome Pharmaceutical Co Ltd
Publication of MX2015011473A publication Critical patent/MX2015011473A/es
Publication of MX374244B publication Critical patent/MX374244B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención proporciona un compuesto novedoso de fosforamidato de nucleósido, o un estereoisómero, una sal, un hidrato, un solvato o un cristal del mismo para el tratamiento de infección viral por familia Flaviviridae, especialmente infección viral de hepatitis C. La presente invención también proporciona la composición farmacéutica que comprende un compuesto de la presente invención, o un estereoisómero, una sal, un hidrato, un solvato o un cristal del mismo y un uso del compuesto o la composición de la presente invención en el tratamiento de infección viral por familia Flaviviridae, especialmente infección viral de hepatitis C. El compuesto de la presente invención tiene un buen efecto anti-HCV.
MX2015011473A 2013-03-08 2014-03-06 Compuesto de fosforamidato de nucleosido novedoso y su uso. MX374244B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310075423 2013-03-08
PCT/CN2014/073004 WO2014135107A1 (zh) 2013-03-08 2014-03-06 新的核苷氨基磷酸酯化合物及其应用

Publications (2)

Publication Number Publication Date
MX2015011473A MX2015011473A (es) 2016-05-31
MX374244B true MX374244B (es) 2025-03-05

Family

ID=51462121

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011473A MX374244B (es) 2013-03-08 2014-03-06 Compuesto de fosforamidato de nucleosido novedoso y su uso.

Country Status (11)

Country Link
US (1) US9963480B2 (es)
EP (1) EP2940031B1 (es)
JP (1) JP6219414B2 (es)
KR (1) KR101857337B1 (es)
CN (4) CN109503686B (es)
AU (1) AU2014225052B2 (es)
BR (1) BR112015020472B1 (es)
CA (1) CA2899763C (es)
MX (1) MX374244B (es)
RU (1) RU2621709C2 (es)
WO (1) WO2014135107A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101857337B1 (ko) 2013-03-08 2018-05-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 신규한 뉴클레오시드 포스포라미데이트 화합물 및 이의 용도
CN104761604A (zh) * 2014-01-02 2015-07-08 江苏豪森药业股份有限公司 尿嘧啶核苷酸类似物及其制备方法和应用
WO2016015638A1 (zh) * 2014-07-30 2016-02-04 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
WO2016023522A2 (en) * 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
WO2016044243A1 (en) * 2014-09-16 2016-03-24 Achillion Pharmaceuticals, Inc. Pyrimidine nucleoside phosphoramidate
CN105348342B (zh) * 2014-09-30 2018-09-21 南京正大天晴制药有限公司 核苷氨基磷酸酯化合物及药物组合物和用途
CN106132972B (zh) * 2015-02-06 2018-08-31 银杏树药业(苏州)有限公司 用于治疗hcv感染的氨基磷酸酯
CN106866737B (zh) * 2015-12-11 2020-11-20 南京圣和药物研发有限公司 膦酸衍生物及其应用
BR112019004297A2 (pt) * 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
WO2018082503A1 (zh) * 2016-11-02 2018-05-11 四川科伦博泰生物医药股份有限公司 杂环化合物及其制备方法和用途
WO2018093717A1 (en) * 2016-11-17 2018-05-24 Abbvie Inc. Compositions and methods for treating hcv infection
CN108218938B (zh) * 2016-12-13 2022-06-07 南京圣和药业股份有限公司 联苯核苷氨基磷酸酯化合物的晶型及其制备方法与用途
CN108218936B (zh) * 2016-12-13 2022-06-07 南京圣和药业股份有限公司 联苯核苷氨基磷酸酯化合物的异构体及其无定型物
CN121221626A (zh) * 2016-12-13 2025-12-30 南京汇诚制药有限公司 新的核苷氨基磷酸脂化合物的组合物及其制备方法
CN108218937B (zh) * 2016-12-13 2022-06-07 南京圣和药业股份有限公司 核苷氨基磷酸酯类化合物的光学异构体及其应用
CN108218939B (zh) * 2016-12-13 2022-05-17 南京汇诚制药有限公司 联苯核苷氨基磷酸酯化合物的新晶型及制备方法
CN108218940A (zh) * 2016-12-13 2018-06-29 南京圣和药业股份有限公司 核苷氨基磷酸酯类化合物、其制备方法及用途
CN108201539B (zh) * 2016-12-16 2022-04-19 南京汇诚制药有限公司 联苯核苷氨基磷酸酯化合物的应用
CN109419806B (zh) * 2017-08-23 2023-06-20 南京圣和药业股份有限公司 抗病毒组合物及其应用
CN108997426B (zh) * 2018-07-19 2020-11-13 大连理工大学 靶向Hsp60的黄酮烷氧基氨基磷酸酯衍生物、制备及应用
JP2022540585A (ja) 2019-07-12 2022-09-16 キャノピー グロウス コーポレイション カンナビノイド誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147175A1 (en) * 2000-11-16 2002-10-10 Shepard H. Michael Synergistic ECTA compositions
CA2523083C (en) * 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20080280842A1 (en) 2004-10-21 2008-11-13 Merck & Co., Inc. Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
GB0503642D0 (en) 2005-02-22 2005-03-30 Younane Paul P M An exercise apparatus
AR056327A1 (es) 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
CA2748057C (en) * 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
JP2014526474A (ja) * 2011-09-12 2014-10-06 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
EA024297B1 (ru) * 2011-12-20 2016-09-30 Рибосайенс Ллк 2',4'-дифтор-2'-метилзамещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
KR101857337B1 (ko) 2013-03-08 2018-05-11 난징 산홈 팔마세우티칼 컴퍼니 리미티드 신규한 뉴클레오시드 포스포라미데이트 화합물 및 이의 용도
CN104761604A (zh) * 2014-01-02 2015-07-08 江苏豪森药业股份有限公司 尿嘧啶核苷酸类似物及其制备方法和应用

Also Published As

Publication number Publication date
JP2016510043A (ja) 2016-04-04
JP6219414B2 (ja) 2017-10-25
WO2014135107A1 (zh) 2014-09-12
US20150361123A1 (en) 2015-12-17
RU2015142682A (ru) 2017-04-13
EP2940031A4 (en) 2016-01-27
KR20150132230A (ko) 2015-11-25
CA2899763C (en) 2020-03-10
CN108546277B (zh) 2021-05-07
CN109503686A (zh) 2019-03-22
AU2014225052B2 (en) 2016-11-10
EP2940031A1 (en) 2015-11-04
CN104031104B (zh) 2018-04-10
CA2899763A1 (en) 2014-09-12
RU2621709C2 (ru) 2017-06-07
KR101857337B1 (ko) 2018-05-11
CN104031104A (zh) 2014-09-10
CN108314697A (zh) 2018-07-24
MX2015011473A (es) 2016-05-31
CN108314697B (zh) 2021-05-07
EP2940031B1 (en) 2017-09-27
US9963480B2 (en) 2018-05-08
HK1210619A1 (en) 2016-04-29
BR112015020472A2 (pt) 2020-01-28
BR112015020472B1 (pt) 2021-01-19
CN108546277A (zh) 2018-09-18
CN109503686B (zh) 2022-03-11
AU2014225052A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
MX374244B (es) Compuesto de fosforamidato de nucleosido novedoso y su uso.
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2013002939A1 (es) Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201492188A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
SMT201500148B (it) Composizioni per uso nel trattamento di infezioni virali
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EA201492205A1 (ru) Макроциклические ингибиторы вирусов flaviviridae
CL2016001509A1 (es) Formas cristalinas de los análogos de sofosbuvir antivirales
CL2016001364A1 (es) Moduladores de ror gamma (rory)
EA202090547A2 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
BR112013002729A2 (pt) inibidores de vírus de hepatite c
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
WO2013106689A8 (en) Hcv ns3 protease inhibitors
MX2017000312A (es) Derivados de isoindolina para usarse en el tratamiento de una infeccion viral.
CL2015002897A1 (es) Inhibidores de bace1
HUE036069T2 (hu) Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére
EA201590770A1 (ru) Ингибиторы вируса гепатита с
IN2014CN00572A (es)

Legal Events

Date Code Title Description
FG Grant or registration